Okava, a biopharmaceutical company, announced this week that it began a pilot study of a GLP-1 drug for cats with obesity. Instead of receiving weekly injections of the medicine as humans do, the cats will get small, injectable implants that will release the drug for up to six months. Initial results are expected next summer. Competing companies are starting research, as well.
Source: The New York Times, December 2, 2025. Link. Okava is aiming to keep the price of its product at or below $100 a month, Dr. (Michael) Klotsman said, pointing out that some people pay more than that for high-end dog food. “We do think the market is there,” he said.